Inclusion Criteria:

- Patients must have histologically or cytologically confirmed stage I or II non-small
cell lung cancer based on the AJCC, 7th edition criteria or have suspicious nodules
which are going to be surgically resected prior to confirming malignancy

- Patients must be deemed to be eligible candidates for either surgery or stereotactic
radiation

- Stereotactic radiation treatment of stage I disease or adjuvant chemotherapy is
allowed at the discretion of treating physician for the participating subject

- Patient who will have surgical resections must consent to the use of post-surgery
tumor samples for correlative molecular studies

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

- Ability to travel to appointments and willingness to participate in this study

- Ability to understand and willingness to sign a written information consent and
Health Insurance Portability and Accountability Act (HIPAA) consent document

Exclusion Criteria:

- Patients who have had a prior lung cancer recurrence within the last five years from
the current diagnosis

- Patients having a prior malignancy within the past 3 years other than complete
resection of basal or squamous cell carcinoma of the skin, any in situ malignancy, or
low-risk prostate cancer after curative therapy

- Patients with any prior systemic therapy for the current diagnosis of lung cancer

- Patients with a diagnosis of advanced stage disease (stage III or IV)

- Patients who are unable to comply with study and/or follow up procedures

- Patients who have uncontrolled intercurrent illness including, but not limited to
psychiatric illness/social situations that would limit compliance with study
requirements

- Patients who are pregnant or are breast feeding